| 1 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 2 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6796).
|
| 3 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6802).
|
| 4 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6805).
|
| 5 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031284)
|
| 6 |
ClinicalTrials.gov (NCT00109538) Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED). U.S. National Institutes of Health.
|
| 7 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 8 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6974).
|
| 9 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
|
| 10 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026615)
|
| 11 |
ClinicalTrials.gov (NCT02999854) Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (HATCY). U.S. National Institutes of Health.
|
| 12 |
J Clin Oncol 33, 2015 (suppl, abstr TPS7097).
|
| 13 |
ClinicalTrials.gov (NCT04313881) Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE). U.S. National Institutes of Health.
|
| 14 |
ClinicalTrials.gov (NCT04313881) Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE). U.S. National Institutes of Health.
|
| 15 |
ClinicalTrials.gov (NCT04266301) Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2). U.S. National Institutes of Health.
|
| 16 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
|
| 17 |
ClinicalTrials.gov (NCT01215188) A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM2). U.S. National Institutes of Health.
|
| 18 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 19 |
ClinicalTrials.gov (NCT03699475) Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE). U.S. National Institutes of Health.
|
| 20 |
Clinical pipeline report, company report or official report of Actinium Pharmaceuticals
|
| 21 |
ClinicalTrials.gov (NCT01124539) Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma. U.S. National Institutes of Health.
|
| 22 |
ClinicalTrials.gov (NCT03824080) Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes. U.S. National Institutes of Health.
|
| 23 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032443)
|
| 24 |
ClinicalTrials.gov (NCT01422486) Phase 2 Study of Telintra in Deletion 5q Myelodysplastic Syndrome. U.S. National Institutes of Health.
|
| 25 |
Targeting mRNA processing as an anticancer strategy. Nat Rev Drug Discov. 2020 Feb;19(2):112-129.
|
| 26 |
ClinicalTrials.gov (NCT02343133) Safety Study of HemaMax (rHuIL-12) to Treat Acute Radiation Syndrome. U.S. National Institutes of Health.
|
| 27 |
ClinicalTrials.gov (NCT04582539) To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.. U.S. National Institutes of Health.
|
| 28 |
ClinicalTrials.gov (NCT04264806) A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT). U.S. National Institutes of Health.
|
| 29 |
ClinicalTrials.gov (NCT04395092) Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM). U.S. National Institutes of Health.
|
| 30 |
ClinicalTrials.gov (NCT00044226) A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).. U.S. National Institutes of Health.
|
| 31 |
ClinicalTrials.gov (NCT03059615) A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS. U.S. National Institutes of Health.
|
| 32 |
ClinicalTrials.gov (NCT01794663) Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function. U.S. National Institutes of Health.
|
| 33 |
ClinicalTrials.gov (NCT04217720) SNS-301 Monotherapy in High Risk MDS and CMML. U.S. National Institutes of Health.
|
| 34 |
ClinicalTrials.gov (NCT04417517) A Study of ALX148 With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02). U.S. National Institutes of Health.
|
| 35 |
ClinicalTrials.gov (NCT04079296) A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health.
|
| 36 |
ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
|
| 37 |
ClinicalTrials.gov (NCT03214666) GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for High Risk Heme Malignancies. U.S. National Institutes of Health.
|
| 38 |
ClinicalTrials.gov (NCT04284228) Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT. U.S. National Institutes of Health.
|
| 39 |
ClinicalTrials.gov (NCT03176277) A Study of ONO-7475 in Patients With Acute Leukemias. U.S. National Institutes of Health.
|
| 40 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8359).
|
| 41 |
ClinicalTrials.gov (NCT03483324) Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation. U.S. National Institutes of Health.
|
| 42 |
ClinicalTrials.gov (NCT03647800) Study of APVO436 in Patients With AML or MDS. U.S. National Institutes of Health.
|
| 43 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 44 |
ClinicalTrials.gov (NCT04771130) A Study of BGB-11417 in Participants With Myeloid Malignancies. U.S. National Institutes of Health.
|
| 45 |
ClinicalTrials.gov (NCT04402541) Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome. U.S. National Institutes of Health.
|
| 46 |
ClinicalTrials.gov (NCT04156256) CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies. U.S. National Institutes of Health.
|
| 47 |
ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
|
| 48 |
ClinicalTrials.gov (NCT04167696) Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1). U.S. National Institutes of Health.
|
| 49 |
ClinicalTrials.gov (NCT03884829) A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS. U.S. National Institutes of Health.
|
| 50 |
ClinicalTrials.gov (NCT04511975) A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS. U.S. National Institutes of Health.
|
| 51 |
ClinicalTrials.gov (NCT03573310) A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS. U.S. National Institutes of Health.
|
| 52 |
ClinicalTrials.gov (NCT03915379) A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health.
|
| 53 |
ClinicalTrials.gov (NCT04139434) Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
|
| 54 |
Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017 Jun;16(6):400-423.
|
| 55 |
ClinicalTrials.gov (NCT03612739) EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
|
| 56 |
ClinicalTrials.gov (NCT04623944) NKX101, Intravenous Allogeneic Engineered Natural Killer Cells, in Adults With AML or MDS. U.S. National Institutes of Health.
|
| 57 |
ClinicalTrials.gov (NCT03927261) A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients With CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome. U.S.National Institutes of Health.
|
| 58 |
ClinicalTrials.gov (NCT04227847) A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies. U.S. National Institutes of Health.
|
| 59 |
ClinicalTrials.gov (NCT04021368) SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome. U.S. National Institutes of Health.
|
| 60 |
ClinicalTrials.gov (NCT04245397) SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy. U.S. National Institutes of Health.
|
| 61 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026289)
|
| 62 |
High methylation of the 4-aminobutyrate aminotransferase gene predicts a poor prognosis in patients with myelodysplastic syndrome.Int J Oncol. 2019 Feb;54(2):491-504. doi: 10.3892/ijo.2018.4652. Epub 2018 Dec 4.
|
| 63 |
Reduced expression of FLIP SHORT in bone marrow of low risk myelodysplastic syndrome.Leuk Res. 2007 Jun;31(6):853-7. doi: 10.1016/j.leukres.2006.11.017. Epub 2007 Jan 31.
|
| 64 |
Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome.Br J Haematol. 2016 Nov;175(3):393-401. doi: 10.1111/bjh.14270. Epub 2016 Sep 9.
|
| 65 |
Comparative analysis of G-CSFR and GM-CSFR expressions on CD34+ cells in patients with aplastic anemia and myelodysplastic syndrome.Int J Lab Hematol. 2009 Dec;31(6):597-602. doi: 10.1111/j.1751-553X.2008.01083.x. Epub 2008 Jul 14.
|
| 66 |
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.Clin Cancer Res. 2018 Mar 1;24(5):1019-1029. doi: 10.1158/1078-0432.CCR-17-1792. Epub 2017 Sep 25.
|
| 67 |
High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.J Transl Med. 2016 Mar 5;14:66. doi: 10.1186/s12967-016-0817-9.
|
| 68 |
Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia.Blood. 2006 Oct 1;108(7):2182-9. doi: 10.1182/blood-2006-01-010249. Epub 2006 Jun 27.
|
| 69 |
ETV6/GOT1 fusion in a case of t(10;12)(q24;p13)-positive myelodysplastic syndrome.Haematologica. 2008 Mar;93(3):467-8. doi: 10.3324/haematol.11988.
|
| 70 |
The Molecular Pathology of Myelodysplastic Syndrome.Pathobiology. 2019;86(1):24-29. doi: 10.1159/000488712. Epub 2018 May 23.
|
| 71 |
Increase of IRF-1 gene expression and impairment of T regulatory cells suppression activity on patients with myelodysplastic syndrome: A longitudinal one-year study.Leuk Res. 2017 Apr;55:6-17. doi: 10.1016/j.leukres.2017.01.008. Epub 2017 Jan 5.
|
| 72 |
Mutation analysis of therapy-related myeloid neoplasms.Cancer Genet. 2018 Apr;222-223:38-45. doi: 10.1016/j.cancergen.2018.02.006. Epub 2018 Mar 8.
|
| 73 |
Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis.Blood Adv. 2019 Nov 26;3(22):3579-3589. doi: 10.1182/bloodadvances.2019000922.
|
| 74 |
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.Cell Stem Cell. 2018 Nov 1;23(5):700-713.e6. doi: 10.1016/j.stem.2018.10.004.
|
| 75 |
Correlation between IL-7 genomic protein methylation level and acute myeloid leukemia.Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1196-1202. doi: 10.26355/eurrev_201902_17012.
|
| 76 |
Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice.Blood Adv. 2017 Aug 18;1(19):1551-1564. doi: 10.1182/bloodadvances.2017008342. eCollection 2017 Aug 22.
|
| 77 |
Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation.Blood. 2019 Nov 14;134(20):1730-1744. doi: 10.1182/blood.2019000170.
|
| 78 |
High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome.Leuk Lymphoma. 2001 Jul;42(3):511-6. doi: 10.3109/10428190109064609.
|
| 79 |
Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines.Leukemia. 1997 Oct;11(10):1605-9. doi: 10.1038/sj.leu.2400812.
|
| 80 |
Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice.Blood. 2018 Oct 4;132(14):1535-1544. doi: 10.1182/blood-2018-05-852798. Epub 2018 Jul 31.
|
| 81 |
Case of late-onset erythropoietic protoporphyria with myelodysplastic syndrome who has homozygous IVS3-48C polymorphism in the ferrochelatase gene.J Dermatol. 2017 Jun;44(6):651-655. doi: 10.1111/1346-8138.13709. Epub 2016 Dec 27.
|
| 82 |
Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndrome.Blood. 2004 Feb 15;103(4):1518-20. doi: 10.1182/blood-2003-09-3222. Epub 2003 Oct 23.
|
| 83 |
CD123 CAR T cells for the treatment of myelodysplastic syndrome.Exp Hematol. 2019 Jun;74:52-63.e3. doi: 10.1016/j.exphem.2019.05.002. Epub 2019 May 25.
|
| 84 |
Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.Blood Adv. 2019 Nov 12;3(21):3406-3418. doi: 10.1182/bloodadvances.2019000564.
|
| 85 |
Plasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow : Summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016.Ann Hematol. 2017 May;96(5):765-777. doi: 10.1007/s00277-017-2947-4. Epub 2017 Feb 12.
|
| 86 |
Aberrant methylation in pediatric myelodysplastic syndrome.Leuk Res. 2007 Feb;31(2):175-81. doi: 10.1016/j.leukres.2006.06.013. Epub 2006 Aug 4.
|
| 87 |
Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.Int J Hematol. 2020 Feb;111(2):182-191. doi: 10.1007/s12185-019-02778-9. Epub 2019 Nov 18.
|
| 88 |
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.Haematologica. 2017 Feb;102(2):308-319. doi: 10.3324/haematol.2016.147835. Epub 2016 Oct 6.
|
| 89 |
Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure.Br J Haematol. 2009 Oct;147(1):102-12. doi: 10.1111/j.1365-2141.2009.07822.x. Epub 2009 Jul 28.
|
| 90 |
Tumor-derived CK1 mutations enhance MDMX inhibition of p53.Oncogene. 2020 Jan;39(1):176-186. doi: 10.1038/s41388-019-0979-z. Epub 2019 Aug 28.
|
| 91 |
RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.Ann Oncol. 2011 Oct;22(10):2208-15. doi: 10.1093/annonc/mdq737. Epub 2011 Feb 16.
|
| 92 |
DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.Leuk Res. 2017 Dec;63:62-71. doi: 10.1016/j.leukres.2017.10.006. Epub 2017 Oct 31.
|
| 93 |
Effects of arsenic disulfide on apoptosis, histone acetylation, toll like receptor 2 activation, and erythropoiesis in bone marrow mononuclear cells of myelodysplastic syndromes patients in vitro. Leuk Res. 2017 Nov;62:4-11. doi: 10.1016/j.leukres.2017.09.010. Epub 2017 Sep 19.
|
| 94 |
Genetic Variant Screening of DNA Repair Genes in Myelodysplastic Syndrome Identifies a Novel Mutation in the XRCC2 Gene.Oncol Res Treat. 2019;42(5):263-268. doi: 10.1159/000497209. Epub 2019 Mar 12.
|
| 95 |
Reduced PLCG1 expression is associated with inferior survival for myelodysplastic syndromes.Cancer Med. 2020 Jan;9(2):460-468. doi: 10.1002/cam4.2717. Epub 2019 Nov 21.
|
| 96 |
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia.Haematologica. 2020 Jun;105(6):1731-1737. doi: 10.3324/haematol.2019.229492. Epub 2019 Oct 3.
|
| 97 |
Germline Genetic Predisposition to Hematologic Malignancy.J Clin Oncol. 2017 Mar 20;35(9):1018-1028. doi: 10.1200/JCO.2016.70.8644. Epub 2017 Feb 13.
|
| 98 |
Gene expression profiling in myelodysplastic syndrome after SPARC overexpression associated with Ara-C.Oncol Rep. 2015 Oct;34(4):2072-82. doi: 10.3892/or.2015.4139. Epub 2015 Jul 20.
|
| 99 |
Activating CBL mutations are associated with a distinct MDS/MPN phenotype.Ann Hematol. 2012 Nov;91(11):1713-20. doi: 10.1007/s00277-012-1521-3. Epub 2012 Aug 10.
|
| 100 |
Transforming growth factor (TGF)- pathway as a therapeutic target in lower risk myelodysplastic syndromes.Leukemia. 2019 Jun;33(6):1303-1312. doi: 10.1038/s41375-019-0448-2. Epub 2019 Apr 8.
|
| 101 |
Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.Int J Hematol. 2017 Aug;106(2):248-257. doi: 10.1007/s12185-017-2237-x. Epub 2017 Apr 12.
|
| 102 |
Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia.Leuk Res. 2004 Nov;28(11):1203-11. doi: 10.1016/j.leukres.2004.03.020.
|
| 103 |
A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome.Genes Chromosomes Cancer. 2002 Sep;35(1):11-9. doi: 10.1002/gcc.10090.
|
| 104 |
Enhanced myeloid specificity of CD117 compared with CD13 and CD33.Leuk Res. 1999 Apr;23(4):341-7. doi: 10.1016/s0145-2126(98)00185-4.
|
| 105 |
Rapamycin and bafilomycin A1 alter autophagy and megakaryopoiesis.Platelets. 2017 Jan;28(1):82-89. doi: 10.1080/09537104.2016.1204436. Epub 2016 Aug 18.
|
| 106 |
Hematopathological alterations of major tumor suppressor cascade, vital cell cycle inhibitors and hematopoietic niche components in experimental myelodysplasia.Chem Biol Interact. 2017 Aug 1;273:1-10. doi: 10.1016/j.cbi.2017.05.014. Epub 2017 May 23.
|
| 107 |
Prognostic importance of Aurora Kinases and mitotic spindle genes transcript levels in Myelodysplastic syndrome.Leuk Res. 2018 Jan;64:61-70. doi: 10.1016/j.leukres.2017.11.013. Epub 2017 Nov 28.
|
| 108 |
Mapping of the human Zn-alpha 2-glycoprotein gene (AZGP1) to chromosome 7q22 by in situ hybridization.Cytogenet Cell Genet. 1994;66(4):263-6. doi: 10.1159/000133708.
|
| 109 |
BMI1 reprogrammes histone acetylation and enhances c-fos pathway via directly binding to Zmym3 in malignant myeloid progression. J Cell Mol Med. 2014 Jun;18(6):1004-17. doi: 10.1111/jcmm.12246. Epub 2014 Feb 27.
|
| 110 |
Repeated sequences in CASPASE-5 and FANCD2 but not NF1 are targets for mutation in microsatellite-unstable acute leukemia/myelodysplastic syndrome.Mol Cancer Res. 2005 May;3(5):251-60. doi: 10.1158/1541-7786.MCR-04-0182.
|
| 111 |
UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.Leukemia. 2016 Mar;30(3):728-39. doi: 10.1038/leu.2015.275. Epub 2015 Oct 9.
|
| 112 |
Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.Blood. 2014 Jul 31;124(5):780-90. doi: 10.1182/blood-2014-01-552463. Epub 2014 Jun 2.
|
| 113 |
Clonal CD5-positive B lymphocytes in myelodysplastic syndrome with systemic vasculitis and trisomy 8.Ann Hematol. 1997 Jan;74(1):37-40. doi: 10.1007/s002770050253.
|
| 114 |
S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes.Leukemia. 2019 Aug;33(8):2034-2046. doi: 10.1038/s41375-019-0397-9. Epub 2019 Feb 8.
|
| 115 |
Management of myelodysplastic syndromes after failure of response to hypomethylating agents.Ther Adv Hematol. 2019 May 9;10:2040620719847059. doi: 10.1177/2040620719847059. eCollection 2019.
|
| 116 |
SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment.Nat Commun. 2015 Dec 8;6:10004. doi: 10.1038/ncomms10004.
|
| 117 |
Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.Clin Cancer Res. 2014 Jul 1;20(13):3589-602. doi: 10.1158/1078-0432.CCR-13-2811. Epub 2014 May 5.
|
| 118 |
Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia.Exp Hematol. 2019 May;73:7-12.e4. doi: 10.1016/j.exphem.2019.02.006. Epub 2019 Feb 28.
|
| 119 |
Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes.Leuk Res. 2017 Jan;52:20-27. doi: 10.1016/j.leukres.2016.11.002. Epub 2016 Nov 2.
|
| 120 |
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4.
|
| 121 |
Proteins of the mitotic checkpoint and spindle are related to chromosomal instability and unfavourable prognosis in patients with myelodysplastic syndrome.J Clin Pathol. 2015 May;68(5):381-7. doi: 10.1136/jclinpath-2014-202728. Epub 2015 Jan 30.
|
| 122 |
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12974-9. doi: 10.1073/pnas.0811267106. Epub 2009 May 26.
|
| 123 |
Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.Int J Cancer. 2016 Sep 15;139(6):1402-13. doi: 10.1002/ijc.30181. Epub 2016 Jun 3.
|
| 124 |
Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors.Sci Transl Med. 2019 Sep 25;11(511):eaaw3781. doi: 10.1126/scitranslmed.aaw3781.
|
| 125 |
Despite differential gene expression profiles pediatric MDS derived mesenchymal stromal cells display functionality in vitro.Stem Cell Res. 2015 Mar;14(2):198-210. doi: 10.1016/j.scr.2015.01.006. Epub 2015 Jan 28.
|
| 126 |
Identification of a novel fusion gene MLL-MAML2 in secondary acute myelogenous leukemia and myelodysplastic syndrome with inv(11)(q21q23).Genes Chromosomes Cancer. 2007 Sep;46(9):813-9. doi: 10.1002/gcc.20467.
|
| 127 |
Expression and genomic configuration of GM-CSF, IL-3, M-CSF receptor (C-FMS), early growth response gene-1 (EGR-1) and M-CSF genes in primary myelodysplastic syndromes.Leuk Lymphoma. 1994 Sep;15(1-2):135-41. doi: 10.3109/10428199409051688.
|
| 128 |
Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction.Blood. 2001 Jul 15;98(2):422-7. doi: 10.1182/blood.v98.2.422.
|
| 129 |
Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34).Int J Lab Hematol. 2017 Aug;39(4):409-417. doi: 10.1111/ijlh.12641. Epub 2017 Mar 20.
|
| 130 |
Relationship between Altered miRNA Expression and DNA Methylation of the DLK1-DIO3 Region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes.Cells. 2018 Sep 14;7(9):138. doi: 10.3390/cells7090138.
|
| 131 |
Identification of microRNA-regulated pathways using an integration of microRNA-mRNA microarray and bioinformatics analysis in CD34+ cells of myelodysplastic syndromes.Sci Rep. 2016 Aug 30;6:32232. doi: 10.1038/srep32232.
|
| 132 |
Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes.Leuk Res. 2013 Mar;37(3):251-8. doi: 10.1016/j.leukres.2012.11.011. Epub 2012 Dec 14.
|
| 133 |
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.Am J Hematol. 2020 Feb;95(2):133-143. doi: 10.1002/ajh.25673. Epub 2019 Nov 18.
|
| 134 |
Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations.Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4004-8. doi: 10.1073/pnas.91.9.4004.
|
| 135 |
Erythropoietin receptor in myelodysplastic syndrome and leukemia.Leuk Lymphoma. 2002 Feb;43(2):261-4. doi: 10.1080/10428190290006026.
|
| 136 |
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.Blood Adv. 2018 Jun 26;2(12):1459-1469. doi: 10.1182/bloodadvances.2017012369.
|
| 137 |
Clinical implications of immunophenotypic abnormalities of bone marrow myeloid cell compartment in myelodysplastic syndromes.J BUON. 2010 Oct-Dec;15(4):746-52.
|
| 138 |
Endoplasmic reticulum protein GliPR1 regulates G protein signaling and the cell cycle and is overexpressed in AML.Oncol Rep. 2013 Nov;30(5):2254-62. doi: 10.3892/or.2013.2716. Epub 2013 Sep 4.
|
| 139 |
Platelet glycoprotein expression in patients with myelodysplastic syndrome.Thromb Res. 2000 Oct 1;100(1):27-34. doi: 10.1016/s0049-3848(00)00302-9.
|
| 140 |
Meeting report: myelodysplastic syndromes at ASH 2007.Leukemia. 2008 May;22(5):893-7. doi: 10.1038/leu.2008.45. Epub 2008 Mar 6.
|
| 141 |
GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia.Cancer Cell. 2016 Jan 11;29(1):61-74. doi: 10.1016/j.ccell.2015.11.012.
|
| 142 |
CD8(+) T cells exhaustion induced by myeloid-derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Gal-9 pathway.J Cell Mol Med. 2020 Jan;24(1):1046-1058. doi: 10.1111/jcmm.14825. Epub 2019 Nov 22.
|
| 143 |
Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway.Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):450-461. doi: 10.1016/j.bbadis.2016.11.013. Epub 2016 Nov 11.
|
| 144 |
Cloning and characterization of human histone deacetylase 8.FEBS Lett. 2000 Jul 28;478(1-2):77-83. doi: 10.1016/s0014-5793(00)01813-5.
|
| 145 |
Single-translocation and double-chimeric transcripts: detection of NUP98-HOXA9 in myeloid leukemias with HOXA11 or HOXA13 breaks of the chromosomal translocation t(7;11)(p15;p15).Blood. 2002 Feb 15;99(4):1428-33. doi: 10.1182/blood.v99.4.1428.
|
| 146 |
Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells.PLoS One. 2017 Feb 8;12(2):e0170470. doi: 10.1371/journal.pone.0170470. eCollection 2017.
|
| 147 |
Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML.Sci Rep. 2018 Sep 17;8(1):13883. doi: 10.1038/s41598-018-32306-4.
|
| 148 |
Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155.Oncogene. 2012 Sep 13;31(37):4085-94. doi: 10.1038/onc.2011.579. Epub 2012 Jan 16.
|
| 149 |
U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.Nat Cell Biol. 2019 May;21(5):640-650. doi: 10.1038/s41556-019-0314-5. Epub 2019 Apr 22.
|
| 150 |
Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis.Blood. 2019 Jul 18;134(3):227-238. doi: 10.1182/blood.2018874214. Epub 2019 Apr 19.
|
| 151 |
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice.Blood Adv. 2018 Oct 9;2(19):2491-2504. doi: 10.1182/bloodadvances.2018024166.
|
| 152 |
Abnormal populations and functions of natural killer cells in patients with myelodysplastic syndromes.Oncol Lett. 2018 Apr;15(4):5497-5504. doi: 10.3892/ol.2018.8062. Epub 2018 Feb 15.
|
| 153 |
Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice.Blood. 2019 May 9;133(19):2069-2078. doi: 10.1182/blood-2018-06-858159. Epub 2019 Feb 11.
|
| 154 |
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.Leukemia. 2013 Sep;27(9):1841-51. doi: 10.1038/leu.2013.193. Epub 2013 Mar 29.
|
| 155 |
Dynamics of clonal evolution in myelodysplastic syndromes.Nat Genet. 2017 Feb;49(2):204-212. doi: 10.1038/ng.3742. Epub 2016 Dec 19.
|
| 156 |
Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes.Exp Hematol. 2000 Oct;28(10):1158-63. doi: 10.1016/s0301-472x(00)00527-0.
|
| 157 |
Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.Br J Haematol. 2011 Mar;152(6):677-87. doi: 10.1111/j.1365-2141.2010.08525.x.
|
| 158 |
Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia.Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):217S-222S. doi: 10.1177/1076029618802363. Epub 2018 Oct 8.
|
| 159 |
Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.Haematologica. 2015 Apr;100(4):472-8. doi: 10.3324/haematol.2014.112755. Epub 2015 Jan 30.
|
| 160 |
Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.Stem Cells Transl Med. 2017 Mar;6(3):840-850. doi: 10.5966/sctm.2016-0034. Epub 2016 Nov 7.
|
| 161 |
RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia.Nat Commun. 2018 Mar 21;9(1):1163. doi: 10.1038/s41467-018-03513-4.
|
| 162 |
Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis.Med Oncol. 2012 Dec;29(4):2359-63. doi: 10.1007/s12032-012-0163-6. Epub 2012 Jan 19.
|
| 163 |
Acute Myeloid Leukemia With Myelodysplasia-Related Changes.Am J Clin Pathol. 2015 Jul;144(1):29-43. doi: 10.1309/AJCP58RSMFRHLHHH.
|
| 164 |
Myeloid maturation potentiates STAT3-mediated atypical IFN- signaling and upregulation of PD-1 ligands in AML and MDS.Sci Rep. 2019 Aug 12;9(1):11697. doi: 10.1038/s41598-019-48256-4.
|
| 165 |
High expression of PIM2 induces HSC proliferation in myelodysplastic syndromes via the IDH1/HIF1- signaling pathway.Oncol Lett. 2019 Jun;17(6):5395-5402. doi: 10.3892/ol.2019.10256. Epub 2019 Apr 16.
|
| 166 |
Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.Ann Hematol. 2011 Sep;90(9):1037-45. doi: 10.1007/s00277-011-1193-4. Epub 2011 Feb 22.
|
| 167 |
The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.Leuk Lymphoma. 2015 Jul;56(7):2123-33. doi: 10.3109/10428194.2014.971407. Epub 2015 Jan 24.
|
| 168 |
Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.Genes Chromosomes Cancer. 2013 Dec;52(12):1167-77. doi: 10.1002/gcc.22112. Epub 2013 Oct 7.
|
| 169 |
Chromosome abnormalities in bone marrow of Fanconi anemia patients.Cancer Genet Cytogenet. 1993 Jan;65(1):47-50. doi: 10.1016/0165-4608(93)90057-s.
|
| 170 |
Immunoglobulin and T-cell receptor delta gene rearrangements are rarely found in myelodysplastic syndromes in chronic phase.Leuk Res. 1994 May;18(5):365-71. doi: 10.1016/0145-2126(94)90020-5.
|
| 171 |
Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows.Int J Hematol. 1999 Aug;70(2):83-90.
|
| 172 |
Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks.Clin Cancer Res. 2019 Sep 15;25(18):5638-5649. doi: 10.1158/1078-0432.CCR-19-0924. Epub 2019 Jul 15.
|
| 173 |
RUNX1 mutation in a patient with myelodysplastic syndrome and decreased erythrocyte expression of blood group A antigen.Transfusion. 2020 Jan;60(1):184-196. doi: 10.1111/trf.15628. Epub 2019 Dec 16.
|
| 174 |
Circulating S100A8 and S100A9 protein levels in plasma of patients with acquired aplastic anemia and myelodysplastic syndromes.Cytokine. 2019 Jan;113:462-465. doi: 10.1016/j.cyto.2018.06.025. Epub 2018 Jun 27.
|
| 175 |
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.J Clin Oncol. 2019 Mar 1;37(7):580-588. doi: 10.1200/JCO.18.00889. Epub 2019 Jan 17.
|
| 176 |
Genetic alterations in 47 patients with a novel myelodysplastic syndrome diagnosis at a single center.Oncol Lett. 2019 Nov;18(5):5077-5084. doi: 10.3892/ol.2019.10853. Epub 2019 Sep 12.
|
| 177 |
SPAG6 silencing induces apoptosis in the myelodysplastic syndrome cell line SKM? via the PTEN/PI3K/AKT signaling pathway in vitro and in vivo.Int J Oncol. 2018 Jul;53(1):297-306. doi: 10.3892/ijo.2018.4390. Epub 2018 May 2.
|
| 178 |
Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells.Int J Hematol. 2008 Apr;87(3):266-75. doi: 10.1007/s12185-008-0052-0. Epub 2008 Feb 20.
|
| 179 |
der(3)t(3;5). Another recurring abnormality in myelodysplastic disorder.Cancer Genet Cytogenet. 1991 Jul 1;54(1):129-31. doi: 10.1016/0165-4608(91)90041-r.
|
| 180 |
Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients.Am J Clin Pathol. 1996 Nov;106(5):680-8. doi: 10.1093/ajcp/106.5.680.
|
| 181 |
Molecular cloning and analysis of the human Tec protein-tyrosine kinase.Leukemia. 1994 Oct;8(10):1663-72.
|
| 182 |
Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.Leukemia. 2013 Apr;27(4):897-906. doi: 10.1038/leu.2012.300. Epub 2012 Oct 17.
|
| 183 |
Uncoupling of CD71 shedding with mitochondrial clearance in reticulocytes in a subset of myelodysplastic syndromes.Leukemia. 2019 Jan;33(1):217-229. doi: 10.1038/s41375-018-0204-z. Epub 2018 Jul 26.
|
| 184 |
Toll-like receptor alterations in myelodysplastic syndrome.Leukemia. 2013 Sep;27(9):1832-40. doi: 10.1038/leu.2013.180. Epub 2013 Jun 14.
|
| 185 |
Deep brain stimulation for myoclonus-dystonia syndrome with double mutations in DYT1 and DYT11.Sci Rep. 2017 Jan 19;7:41042. doi: 10.1038/srep41042.
|
| 186 |
Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.Leukemia. 2016 Mar;30(3):536-44. doi: 10.1038/leu.2015.297. Epub 2015 Oct 26.
|
| 187 |
Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53() murine model.Oncoimmunology. 2018 Jul 30;7(9):e1468954. doi: 10.1080/2162402X.2018.1468954. eCollection 2018.
|
| 188 |
3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.Leuk Res. 2018 Feb;65:25-28. doi: 10.1016/j.leukres.2017.12.004. Epub 2017 Dec 23.
|
| 189 |
Ultra-Sensitive CSF3R Deep Sequencing in Patients With Severe Congenital Neutropenia.Front Immunol. 2019 Feb 28;10:116. doi: 10.3389/fimmu.2019.00116. eCollection 2019.
|
| 190 |
Functional impairment of the HIPK2 small ubiquitin-like modifier (SUMO)-interacting motif in acute myeloid leukemia.Am J Cancer Res. 2019 Jan 1;9(1):94-107. eCollection 2019.
|
| 191 |
Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients.Leuk Res. 2012 Oct;36(10):1300-3. doi: 10.1016/j.leukres.2012.06.010. Epub 2012 Jul 9.
|
| 192 |
A novel monoclonal antibody, KOR-SA3544 which reacts to Philadelphia chromosome-positive acute lymphoblastic leukemia cells with high sensitivity.Leukemia. 1995 Jul;9(7):1233-9.
|
| 193 |
Aberrant methylation of the M-type phospholipase A(2) receptor gene in leukemic cells.BMC Cancer. 2012 Dec 5;12:576. doi: 10.1186/1471-2407-12-576.
|
| 194 |
Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.Leukemia. 2015 Jan;29(1):188-95. doi: 10.1038/leu.2014.170. Epub 2014 May 23.
|
| 195 |
Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.Leukemia. 2016 Dec;30(12):2322-2331. doi: 10.1038/leu.2016.149. Epub 2016 May 23.
|
| 196 |
Downregulation of carnitine acyltransferases and organic cation transporter OCTN2 in mononuclear cells in healthy elderly and patients with myelodysplastic syndromes.J Mol Med (Berl). 2003 Jul;81(7):435-42. doi: 10.1007/s00109-003-0447-6. Epub 2003 Jun 12.
|
| 197 |
Spectrum of complex chromosomal aberrations in a myelodysplastic syndrome and a brief review.J Cancer Res Ther. 2016 Jul-Sep;12(3):1203-1206. doi: 10.4103/0973-1482.197563.
|
| 198 |
Applying a Weight-of-Evidence Approach to Evaluate Relevance of Molecular Landscapes in the Exposure-Disease Paradigm.Biomed Res Int. 2015;2015:515798. doi: 10.1155/2015/515798. Epub 2015 Aug 3.
|
| 199 |
Genetic analysis and clinical picture of severe congenital neutropenia in Israel.Pediatr Blood Cancer. 2015 Jan;62(1):103-8. doi: 10.1002/pbc.25251. Epub 2014 Oct 4.
|
| 200 |
Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.Leukemia. 2015 May;29(5):1092-103. doi: 10.1038/leu.2014.331. Epub 2014 Nov 27.
|
| 201 |
Methylation and expression of mismatch repair gene human mutS homolog 2 in myelodysplastic syndromes.Exp Ther Med. 2018 Jan;15(1):500-505. doi: 10.3892/etm.2017.5402. Epub 2017 Oct 30.
|
| 202 |
Treatment-related myelodysplastic syndrome in a child with acute myeloid leukemia and TPMT heterozygosity.J Pediatr Hematol Oncol. 2015 May;37(4):e242-4. doi: 10.1097/MPH.0000000000000211.
|
| 203 |
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.Leukemia. 2014 Mar;28(3):621-8. doi: 10.1038/leu.2013.330. Epub 2013 Nov 6.
|
| 204 |
Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13).Genes Chromosomes Cancer. 1999 Nov;26(3):192-202. doi: 10.1002/(sici)1098-2264(199911)26:3<192::aid-gcc2>3.0.co;2-e.
|
| 205 |
Semi-quantitative study of calcitonin gene methylation in myelodysplastic syndrome.Chin Med J (Engl). 1998 Aug;111(8):690-3.
|
| 206 |
A diagnosis of discernment: Identifying a novel ATRX mutation in myelodysplastic syndrome with acquired -thalassemia.Cancer Genet. 2019 Feb;231-232:36-40. doi: 10.1016/j.cancergen.2019.01.002. Epub 2019 Jan 9.
|
| 207 |
Mutations within the FLR exon of NF1 are rare in myelodysplastic syndromes and acute myelocytic leukemias.Leukemia. 1993 Jul;7(7):1058-60.
|
| 208 |
Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.Cancer Genet Cytogenet. 2005 Mar;157(2):104-8. doi: 10.1016/j.cancergencyto.2004.06.014.
|
| 209 |
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.Am J Hematol. 2019 Jul;94(7):757-766. doi: 10.1002/ajh.25486. Epub 2019 May 7.
|
| 210 |
Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia.Oncogene. 2007 Apr 5;26(16):2299-307. doi: 10.1038/sj.onc.1210043. Epub 2006 Oct 16.
|
| 211 |
Sequence variations in mitochondrial ferritin: distribution in healthy controls and different types of patients.Genet Test Mol Biomarkers. 2010 Dec;14(6):793-6. doi: 10.1089/gtmb.2010.0076. Epub 2010 Oct 12.
|
| 212 |
LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia.Leukemia. 2020 Mar;34(3):746-758. doi: 10.1038/s41375-019-0614-6. Epub 2019 Nov 1.
|
| 213 |
In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.Ann Hematol. 2005 Dec;84 Suppl 1:32-8. doi: 10.1007/s00277-005-0004-1.
|
| 214 |
Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT.Blood. 2016 Jul 7;128(1):120-9. doi: 10.1182/blood-2015-12-686238. Epub 2016 May 9.
|
| 215 |
Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.J Cancer Res Clin Oncol. 2018 Jun;144(6):1037-1047. doi: 10.1007/s00432-018-2627-3. Epub 2018 Mar 16.
|
| 216 |
Abnormal CD25 expression on hematopoietic cells in myelodysplastic syndromes.Leuk Res. 2018 Apr;67:12-16. doi: 10.1016/j.leukres.2017.11.010. Epub 2017 Dec 15.
|
| 217 |
JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.Cancer Cell. 2018 Nov 12;34(5):741-756.e8. doi: 10.1016/j.ccell.2018.10.008.
|
| 218 |
Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?.Med Oncol. 2019 Oct 30;36(12):99. doi: 10.1007/s12032-019-1324-7.
|
| 219 |
Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics.Am J Hematol. 2009 May;84(5):308-9. doi: 10.1002/ajh.21396.
|
| 220 |
Myeloid neoplasms with eosinophilia.Blood. 2017 Feb 9;129(6):704-714. doi: 10.1182/blood-2016-10-695973. Epub 2016 Dec 27.
|
| 221 |
RUNX1-PDCD6 fusion resulting from a novel t(5;21)(p15;q22) chromosome translocation in myelodysplastic syndrome secondary to chronic lymphocytic leukemia.PLoS One. 2018 Apr 19;13(4):e0196181. doi: 10.1371/journal.pone.0196181. eCollection 2018.
|
| 222 |
RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.Cancer Res. 2007 Mar 1;67(5):1997-2005. doi: 10.1158/0008-5472.CAN-06-3093.
|
| 223 |
PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.Oncotarget. 2017 May 2;8(18):29887-29905. doi: 10.18632/oncotarget.15136.
|
| 224 |
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.J Clin Oncol. 2009 Feb 10;27(5):782-90. doi: 10.1200/JCO.2008.19.3748. Epub 2008 Dec 29.
|
| 225 |
Ribosomal protein L23 negatively regulates cellular apoptosis via the RPL23/Miz-1/c-Myc circuit in higher-risk myelodysplastic syndrome.Sci Rep. 2017 May 24;7(1):2323. doi: 10.1038/s41598-017-02403-x.
|
| 226 |
MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF- pathways.Blood Adv. 2019 Sep 24;3(18):2751-2763. doi: 10.1182/bloodadvances.2019000537.
|
| 227 |
Human TM9SF4 Is a New Gene Down-Regulated by Hypoxia and Involved in Cell Adhesion of Leukemic Cells.PLoS One. 2015 May 11;10(5):e0126968. doi: 10.1371/journal.pone.0126968. eCollection 2015.
|
| 228 |
Penumbra encodes a novel tetraspanin that is highly expressed in erythroid progenitors and promotes effective erythropoiesis.Blood. 2007 Apr 15;109(8):3244-52. doi: 10.1182/blood-2006-09-046672. Epub 2006 Dec 7.
|
| 229 |
Examination of copy number variations of CHST9 in multiple types of hematologic malignancies.Cancer Genet Cytogenet. 2010 Dec;203(2):176-9. doi: 10.1016/j.cancergencyto.2010.07.132.
|
| 230 |
ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.Oncogene. 2009 Feb 26;28(8):1099-109. doi: 10.1038/onc.2008.457. Epub 2008 Dec 15.
|
| 231 |
A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.Nat Med. 2016 Jul;22(7):727-34. doi: 10.1038/nm.4127. Epub 2016 Jun 13.
|
| 232 |
FLT3 mutation and AML/ETO in a case of Myelodysplastic syndrome in transformation corroborates the two hit model of leukemogenesis.Leuk Res. 2007 Jul;31(7):1015-8. doi: 10.1016/j.leukres.2006.09.018. Epub 2006 Oct 31.
|
| 233 |
Alterations in the colorectal carcinoma gene and protein in a novel human myeloid leukemia cell line with trisomy 18 established from overt leukemia after myelodysplastic syndrome.Int J Hematol. 1998 Feb;67(2):153-64. doi: 10.1016/s0925-5710(97)00106-0.
|
| 234 |
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.Blood. 2019 Feb 21;133(8):790-794. doi: 10.1182/blood-2018-11-876888. Epub 2019 Jan 2.
|
| 235 |
Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes.Haematologica. 2012 Jun;97(6):895-902. doi: 10.3324/haematol.2011.057158. Epub 2012 Jan 22.
|
| 236 |
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.Haematologica. 2018 Aug;103(8):1288-1297. doi: 10.3324/haematol.2018.188193. Epub 2018 May 17.
|
| 237 |
CD41 immune staining of micromegakaryocytes improves the diagnosis of myelodysplastic syndrome and differentiation from pancytopenia.Leuk Res. 2018 Mar;66:15-19. doi: 10.1016/j.leukres.2017.10.004. Epub 2017 Oct 18.
|
| 238 |
Detection of t(3;5) and NPM1/MLF1 rearrangement in an elderly patient with acute myeloid leukemia: clinical and laboratory study with review of the literature.Cancer Genet Cytogenet. 2010 Jun;199(2):101-9. doi: 10.1016/j.cancergencyto.2010.02.009.
|
| 239 |
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.Ann Oncol. 2016 Jan;27(1):62-8. doi: 10.1093/annonc/mdv488. Epub 2015 Oct 26.
|
| 240 |
Hereditary myeloid malignancies.Best Pract Res Clin Haematol. 2019 Jun;32(2):163-176. doi: 10.1016/j.beha.2019.05.001. Epub 2019 May 3.
|
| 241 |
High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype.Leukemia. 1993 Jul;7(7):963-9.
|
| 242 |
Establishment and molecular characterization of decitabine-resistant K562 cells.J Cell Mol Med. 2019 May;23(5):3317-3324. doi: 10.1111/jcmm.14221. Epub 2019 Feb 22.
|
| 243 |
Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model.Blood. 2012 Oct 11;120(15):3089-97. doi: 10.1182/blood-2012-01-405332. Epub 2012 Aug 27.
|
| 244 |
Downregulation of microRNA-144 inhibits proliferation and promotes the apoptosis of myelodysplastic syndrome cells through the activation of the AKAP12-dependent ERK1/2 signaling pathway.Cell Signal. 2020 Apr;68:109493. doi: 10.1016/j.cellsig.2019.109493. Epub 2019 Dec 3.
|
| 245 |
Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10years and future perspectives.Wien Klin Wochenschr. 2018 Sep;130(17-18):517-529. doi: 10.1007/s00508-018-1355-7. Epub 2018 Jul 13.
|
| 246 |
A novel gene, ANKRD28 on 3p25, is fused with NUP98 on 11p15 in a cryptic 3-way translocation of t(3;5;11)(p25;q35;p15) in an adult patient with myelodysplastic syndrome/acute myelogenous leukemia.Int J Hematol. 2007 Oct;86(3):238-45. doi: 10.1532/IJH97.07054.
|
| 247 |
Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study.Blood. 2012 Mar 8;119(10):2409-16. doi: 10.1182/blood-2011-08-372573. Epub 2011 Oct 31.
|
| 248 |
Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis.Tumour Biol. 2013 Feb;34(1):165-72. doi: 10.1007/s13277-012-0524-y. Epub 2012 Sep 28.
|
| 249 |
Loss of Asxl2 leads to myeloid malignancies in mice.Nat Commun. 2017 Jun 8;8:15456. doi: 10.1038/ncomms15456.
|
| 250 |
Induction of a hematological and cytogenetic remission in a patient with a myelodysplastic syndrome secondary to Fanconi's anemia employing the S-HAM regimen.Ann Hematol. 1997 Jun;74(6):275-7. doi: 10.1007/s002770050299.
|
| 251 |
Atg3 Overexpression Enhances Bortezomib-Induced Cell Death in SKM-1 Cell.PLoS One. 2016 Jul 8;11(7):e0158761. doi: 10.1371/journal.pone.0158761. eCollection 2016.
|
| 252 |
Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.Clin Lymphoma Myeloma. 2009 Jun;9(3):E10-3. doi: 10.3816/CLM.2009.n.053.
|
| 253 |
Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System.Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):656-664. doi: 10.1016/j.clml.2019.06.003. Epub 2019 Jun 27.
|
| 254 |
Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.J Clin Pathol. 2020 Apr;73(4):209-212. doi: 10.1136/jclinpath-2019-206132. Epub 2019 Nov 26.
|
| 255 |
C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies.Int J Hematol. 2018 Dec;108(6):652-657. doi: 10.1007/s12185-018-2514-3. Epub 2018 Aug 6.
|
| 256 |
Use of a Blast Dominance-Hematogone Index for the Flow Cytometric Evaluation of Myelodysplastic Syndrome (MDS).Am J Clin Pathol. 2019 May 3;151(6):584-592. doi: 10.1093/ajcp/aqz004.
|
| 257 |
Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients.PLoS One. 2016 Nov 30;11(11):e0165582. doi: 10.1371/journal.pone.0165582. eCollection 2016.
|
| 258 |
Impaired Mitophagy of Nucleated Erythroid Cells Leads to Anemia in Patients with Myelodysplastic Syndromes.Oxid Med Cell Longev. 2018 Jun 3;2018:6328051. doi: 10.1155/2018/6328051. eCollection 2018.
|
| 259 |
Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1).Leukemia. 2020 Feb;34(2):404-415. doi: 10.1038/s41375-019-0578-6. Epub 2019 Oct 1.
|
| 260 |
Ex Vivo CD34(+)-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.Biol Blood Marrow Transplant. 2017 Mar;23(3):452-458. doi: 10.1016/j.bbmt.2016.12.633. Epub 2016 Dec 23.
|
| 261 |
Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia.Front Oncol. 2018 Apr 26;8:129. doi: 10.3389/fonc.2018.00129. eCollection 2018.
|
| 262 |
Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes.Am J Transl Res. 2017 Feb 15;9(2):454-465. eCollection 2017.
|
| 263 |
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).J Clin Oncol. 2004 Mar 15;22(6):1078-86. doi: 10.1200/JCO.2004.07.048.
|
| 264 |
Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia.J Clin Oncol. 2002 Oct 15;20(20):4249-54. doi: 10.1200/JCO.2002.11.507.
|
| 265 |
Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis.Br J Haematol. 2000 Dec;111(3):817-25.
|
| 266 |
High frequency of several PIG-A mutations in patients with aplastic anemia and myelodysplastic syndrome.Leukemia. 2006 Apr;20(4):627-34. doi: 10.1038/sj.leu.2404135.
|
| 267 |
Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?.Expert Opin Ther Targets. 2018 May;22(5):381-383. doi: 10.1080/14728222.2018.1464140. Epub 2018 Apr 20.
|
| 268 |
miR-378 inhibits cell growth and enhances apoptosis in human myelodysplastic syndromes.Int J Oncol. 2016 Nov;49(5):1921-1930. doi: 10.3892/ijo.2016.3689. Epub 2016 Sep 13.
|
| 269 |
Identification of NKIAMRE, the human homologue to the mitogen-activated protein kinase-/cyclin-dependent kinase-related protein kinase NKIATRE, and its loss in leukemic blasts with chromosome arm 5q deletion.Cancer Res. 1999 Aug 15;59(16):4069-74.
|
| 270 |
Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes.Leuk Res. 1997 Mar;21(3):235-40. doi: 10.1016/s0145-2126(96)00115-4.
|
| 271 |
Reduced expression of flavocytochrome b558, a component of the NADPH oxidase complex, in neutrophils from patients with myelodysplasia.Exp Hematol. 2003 Sep;31(9):752-9. doi: 10.1016/s0301-472x(03)00188-7.
|
| 272 |
C/EBP-epsilon: chromosomal mapping and mutational analysis of the gene in leukemia and preleukemia.Leuk Res. 1997 Sep;21(9):833-9. doi: 10.1016/s0145-2126(97)00072-6.
|
| 273 |
Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy.Exp Hematol. 2009 Feb;37(2):215-224. doi: 10.1016/j.exphem.2008.10.012.
|
| 274 |
Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.J Cell Physiol. 2018 Jun;233(6):4707-4714. doi: 10.1002/jcp.26253. Epub 2018 Jan 15.
|
| 275 |
Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype.Blood. 2002 Oct 1;100(7):2572-7. doi: 10.1182/blood-2001-11-0026.
|
| 276 |
Myelodysplastic syndromes are induced by histone methylationaltering ASXL1 mutations.J Clin Invest. 2013 Nov;123(11):4627-40. doi: 10.1172/JCI70739.
|
| 277 |
Progression from myelodysplastic syndrome to acute lymphoblastic leukaemia with Philadelphia chromosome and p190 BCR-ABL transcript.Br J Haematol. 1996 May;93(2):389-91. doi: 10.1046/j.1365-2141.1996.4931034.x.
|
| 278 |
Prognostic Impact of Immunohistochemical p53 Expression in Bone Marrow Biopsy in Higher Risk MDS: a Pilot Study.Mediterr J Hematol Infect Dis. 2019 Mar 1;11(1):e2019015. doi: 10.4084/MJHID.2019.015. eCollection 2019.
|
| 279 |
C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia.Cancer Res. 2004 Nov 15;64(22):8443-50. doi: 10.1158/0008-5472.CAN-04-1659.
|
| 280 |
AML1-FOG2 fusion protein in myelodysplasia.Blood. 2005 Jun 1;105(11):4523-6. doi: 10.1182/blood-2004-07-2762. Epub 2005 Feb 10.
|
| 281 |
Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure.Br J Haematol. 2019 Jun;185(5):935-939. doi: 10.1111/bjh.15862. Epub 2019 Mar 19.
|
| 282 |
Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome.Clin Chem Lab Med. 2014 Dec;52(12):1859-65. doi: 10.1515/cclm-2014-0446.
|
| 283 |
Distinct clinical and biological implications of CUX1 in myeloid neoplasms.Blood Adv. 2019 Jul 23;3(14):2164-2178. doi: 10.1182/bloodadvances.2018028423.
|
| 284 |
Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes.Blood. 2004 Jan 15;103(2):698-700. doi: 10.1182/blood-2003-07-2249. Epub 2003 Sep 22.
|
| 285 |
Derivative (1)t(1;16)(p11;p11.1) in myelodysplastic syndrome: a case report and review of the literature.Cancer Genet Cytogenet. 2010 Jan 1;196(1):89-92. doi: 10.1016/j.cancergencyto.2009.07.003.
|
| 286 |
5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.Oncogene. 2009 Oct 1;28(39):3429-41. doi: 10.1038/onc.2009.207. Epub 2009 Jul 13.
|
| 287 |
Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms.J Clin Invest. 2005 Sep;115(9):2351-62. doi: 10.1172/JCI24177. Epub 2005 Aug 25.
|
| 288 |
Hypermethylation of DLX4 predicts poor clinical outcome in patients with myelodysplastic syndrome.Clin Chem Lab Med. 2016 May;54(5):865-71. doi: 10.1515/cclm-2015-0536.
|
| 289 |
Myelodysplastic syndrome with hypereosinophilia and a nonrandom chromosomal abnormality dic(1;7): confirmation of eosinophil clonal involvement by fluorescence in situ hybridization.Cancer Genet Cytogenet. 1998 Nov;107(1):65-8. doi: 10.1016/s0165-4608(98)00055-7.
|
| 290 |
Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients.Haematologica. 2012 Aug;97(8):1218-24. doi: 10.3324/haematol.2011.054437. Epub 2012 Feb 27.
|
| 291 |
Retracted: EBF1 gene promotes the proliferation and inhibits the apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome through negative regulation of mitogen-activated protein kinase axis.J Cell Biochem. 2019 Feb;120(2):1407-1419. doi: 10.1002/jcb.27177. Epub 2018 Oct 18.
|
| 292 |
Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells.Blood. 2004 Oct 15;104(8):2425-31. doi: 10.1182/blood-2004-05-1839. Epub 2004 Jun 24.
|
| 293 |
A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.Sci Transl Med. 2019 Jul 10;11(500):eaav5467. doi: 10.1126/scitranslmed.aav5467.
|
| 294 |
Increased separase activity and occurrence of centrosome aberrations concur with transformation of MDS.PLoS One. 2018 Jan 25;13(1):e0191734. doi: 10.1371/journal.pone.0191734. eCollection 2018.
|
| 295 |
Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols.Leuk Res. 2019 Jun;81:35-42. doi: 10.1016/j.leukres.2019.03.006. Epub 2019 Mar 27.
|
| 296 |
Gene expression profiling of the bone marrow mononuclear cells from patients with myelodysplastic syndrome.Oncol Rep. 2005 Nov;14(5):1189-97.
|
| 297 |
Late-appearing Philadelphia chromosome in a patient with acute nonlymphocytic leukaemia derived from myelodysplastic syndrome: detection of P210- and P190-type bcr/abl fusion gene transcripts at the leukaemic stage.Br J Haematol. 1994 May;87(1):51-6. doi: 10.1111/j.1365-2141.1994.tb04869.x.
|
| 298 |
Discussing and managing hematologic germ line variants.Blood. 2016 Nov 24;128(21):2497-2503. doi: 10.1182/blood-2016-06-716704.
|
| 299 |
Essential role of FBXL5-mediated cellular iron homeostasis in maintenance of hematopoietic stem cells.Nat Commun. 2017 Jul 17;8:16114. doi: 10.1038/ncomms16114.
|
| 300 |
Mechanisms of Impaired Neutrophil Migration by MicroRNAs in Myelodysplastic Syndromes.J Immunol. 2017 Mar 1;198(5):1887-1899. doi: 10.4049/jimmunol.1600622. Epub 2017 Jan 27.
|
| 301 |
MDS shows a higher expression of hTERT and alternative splice variants in unactivated T-cells.Oncotarget. 2016 Nov 1;7(44):71904-71914. doi: 10.18632/oncotarget.12115.
|
| 302 |
Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.Blood. 2011 Oct 27;118(17):4666-73. doi: 10.1182/blood-2010-12-324715. Epub 2011 Aug 26.
|
| 303 |
Haematopoietic and immune defects associated with GATA2 mutation.Br J Haematol. 2015 Apr;169(2):173-87. doi: 10.1111/bjh.13317. Epub 2015 Feb 23.
|
| 304 |
Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome.Blood. 2008 Apr 1;111(7):3802-12. doi: 10.1182/blood-2007-07-096065. Epub 2008 Jan 14.
|
| 305 |
Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/-Catenin Activation.Cancer Res. 2017 Sep 15;77(18):4846-4857. doi: 10.1158/0008-5472.CAN-17-0282. Epub 2017 Jul 6.
|
| 306 |
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.Blood. 2009 Feb 5;113(6):1315-25. doi: 10.1182/blood-2008-06-163246. Epub 2008 Oct 2.
|
| 307 |
GAB2 is a novel target of 11q amplification in AML/MDS.Genes Chromosomes Cancer. 2006 Sep;45(9):798-807. doi: 10.1002/gcc.20344.
|
| 308 |
The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
|
| 309 |
Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome.Haematologica. 2018 Apr;103(4):614-625. doi: 10.3324/haematol.2017.167288. Epub 2018 Jan 11.
|
| 310 |
Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level.Ann Hematol. 2012 Jan;91(1):39-46. doi: 10.1007/s00277-011-1242-z. Epub 2011 May 7.
|
| 311 |
NKL homeobox gene activities in normal and malignant myeloid cells.PLoS One. 2019 Dec 11;14(12):e0226212. doi: 10.1371/journal.pone.0226212. eCollection 2019.
|
| 312 |
GPR68: An Emerging Drug Target in Cancer.Int J Mol Sci. 2019 Jan 28;20(3):559. doi: 10.3390/ijms20030559.
|
| 313 |
Purification of Bone Marrow Clonal Cells from Patients with Myelodysplastic Syndrome via IGF-IR.PLoS One. 2015 Oct 15;10(10):e0140372. doi: 10.1371/journal.pone.0140372. eCollection 2015.
|
| 314 |
Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders.Leuk Res. 2007 Feb;31(2):147-55. doi: 10.1016/j.leukres.2006.04.010. Epub 2006 Jun 5.
|
| 315 |
Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23.
|
| 316 |
Clinical significance of hyaluronan levels and its pro-osteogenic effect on mesenchymal stromal cells in myelodysplastic syndromes.J Transl Med. 2018 Aug 24;16(1):234. doi: 10.1186/s12967-018-1614-4.
|
| 317 |
Decitabine treatment could ameliorate primary iron-overload in myelodysplastic syndrome patients.Cancer Invest. 2015 Apr;33(4):98-106. doi: 10.3109/07357907.2014.1001895. Epub 2015 Feb 20.
|
| 318 |
Natural killer expansion, human leukocyte antigens-E expression and CD14(+) CD56(+) monocytes in a myelodysplastic syndrome patient.Eur J Haematol. 2013 Sep;91(3):265-269. doi: 10.1111/ejh.12152. Epub 2013 Jun 28.
|
| 319 |
A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination.Leukemia. 2019 Jul;33(7):1773-1782. doi: 10.1038/s41375-019-0385-0. Epub 2019 Jan 29.
|
| 320 |
Leptin-deficient obesity prolongs survival in a murine model of myelodysplastic syndrome.Haematologica. 2018 Apr;103(4):597-606. doi: 10.3324/haematol.2017.181958. Epub 2018 Jan 25.
|
| 321 |
Clinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome.Eur J Med Res. 2015 Feb 20;20(1):16. doi: 10.1186/s40001-015-0092-x.
|
| 322 |
Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.Ann Hematol. 2012 Dec;91(12):1887-95. doi: 10.1007/s00277-012-1538-7. Epub 2012 Aug 9.
|
| 323 |
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.Blood. 2006 Jul 1;108(1):337-45. doi: 10.1182/blood-2005-12-4769. Epub 2006 Mar 9.
|
| 324 |
A new recurrent chromosomal translocation t(3;11)(q13;q14) in myelodysplastic syndromes associated with overexpression of the ILDR1 gene.Leuk Res. 2012 Jul;36(7):852-6. doi: 10.1016/j.leukres.2012.01.026. Epub 2012 Feb 25.
|
| 325 |
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.Leukemia. 2018 Jun;32(6):1380-1392. doi: 10.1038/s41375-018-0089-x. Epub 2018 Mar 6.
|
| 326 |
Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).Leukemia. 2010 Nov;24(11):1875-84. doi: 10.1038/leu.2010.182. Epub 2010 Aug 26.
|
| 327 |
The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.PLoS One. 2014 Sep 16;9(9):e107817. doi: 10.1371/journal.pone.0107817. eCollection 2014.
|
| 328 |
Epigenetic drug library screening identified an LSD1 inhibitor to target UTX-deficient cells for differentiation therapy.Signal Transduct Target Ther. 2019 Apr 26;4:11. doi: 10.1038/s41392-019-0040-2. eCollection 2019.
|
| 329 |
Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes*.Eur J Haematol. 2010 Apr;84(4):298-303. doi: 10.1111/j.1600-0609.2009.01389.x. Epub 2009 Nov 28.
|
| 330 |
Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis.PLoS One. 2016 Sep 9;11(9):e0162515. doi: 10.1371/journal.pone.0162515. eCollection 2016.
|
| 331 |
Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells.Genes Chromosomes Cancer. 2004 Nov;41(3):203-13. doi: 10.1002/gcc.20087.
|
| 332 |
The lower risk MDS patient at risk of rapid progression.Leuk Res. 2010 Dec;34(12):1551-5. doi: 10.1016/j.leukres.2010.05.023. Epub 2010 Jun 22.
|
| 333 |
Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia. Leukemia. 2005 Nov;19(11):1941-7. doi: 10.1038/sj.leu.2403836.
|
| 334 |
Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis.Lancet Haematol. 2017 Apr;4(4):e183-e191. doi: 10.1016/S2352-3026(17)30029-7. Epub 2017 Mar 16.
|
| 335 |
Overexpression of MCM2 in myelodysplastic syndromes: association with bone marrow cell apoptosis and peripheral cytopenia.Exp Mol Pathol. 2012 Feb;92(1):160-6. doi: 10.1016/j.yexmp.2011.11.003. Epub 2011 Nov 15.
|
| 336 |
MCM3AP and POMP Mutations Cause a DNA-Repair and DNA-Damage-Signaling Defect in an Immunodeficient Child.Hum Mutat. 2016 Mar;37(3):257-68. doi: 10.1002/humu.22939. Epub 2015 Dec 30.
|
| 337 |
A landscape of germ line mutations in a cohort of inherited bone marrow failure patients.Blood. 2018 Feb 15;131(7):717-732. doi: 10.1182/blood-2017-09-806489. Epub 2017 Nov 16.
|
| 338 |
Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway.Cell Death Dis. 2018 May 1;9(5):515. doi: 10.1038/s41419-018-0552-7.
|
| 339 |
Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes.Leukemia. 2020 Mar;34(3):872-881. doi: 10.1038/s41375-019-0623-5. Epub 2019 Nov 12.
|
| 340 |
Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene.Am J Hematol. 2011 Dec;86(12):993-7. doi: 10.1002/ajh.22161. Epub 2011 Sep 22.
|
| 341 |
MicroRNA?43 increases cell apoptosis in myelodysplastic syndrome through the Fas/FasL pathway both invitro and invivo.Int J Oncol. 2018 Nov;53(5):2191-2199. doi: 10.3892/ijo.2018.4534. Epub 2018 Aug 22.
|
| 342 |
Dysregulated human myeloid nuclear differentiation antigen expression in myelodysplastic syndromes: evidence for a role in apoptosis.Cancer Res. 2006 May 1;66(9):4645-51. doi: 10.1158/0008-5472.CAN-06-0229.
|
| 343 |
Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells.Front Immunol. 2019 Jun 11;10:1325. doi: 10.3389/fimmu.2019.01325. eCollection 2019.
|
| 344 |
Hepatocerebral form of mitochondrial DNA depletion syndrome due to mutation in MPV17 gene.Saudi J Gastroenterol. 2012 Jul-Aug;18(4):285-9. doi: 10.4103/1319-3767.98439.
|
| 345 |
Prognostic impact of p15 gene aberrations in acute leukemia.Leuk Lymphoma. 2017 Feb;58(2):257-265. doi: 10.1080/10428194.2016.1201574. Epub 2016 Jul 12.
|
| 346 |
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.Clin Cancer Res. 2018 May 15;24(10):2294-2303. doi: 10.1158/1078-0432.CCR-17-2824. Epub 2018 Feb 20.
|
| 347 |
MYBL2 Supports DNA Double Strand Break Repair in Hematopoietic Stem Cells.Cancer Res. 2018 Oct 15;78(20):5767-5779. doi: 10.1158/0008-5472.CAN-18-0273. Epub 2018 Aug 6.
|
| 348 |
The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes.Leuk Lymphoma. 2017 Nov;58(11):2582-2587. doi: 10.1080/10428194.2017.1312380. Epub 2017 May 9.
|
| 349 |
Neutrophilic Panniculitis in a child with MYSM1 deficiency.Pediatr Dermatol. 2019 Mar;36(2):258-259. doi: 10.1111/pde.13757. Epub 2019 Feb 12.
|
| 350 |
Association between mitochondrial DNA haplogroup and myelodysplastic syndromes.Genes Chromosomes Cancer. 2016 Sep;55(9):688-93. doi: 10.1002/gcc.22370. Epub 2016 Jun 21.
|
| 351 |
High expression of ERCC1, FLT1, NME4 and PCNA associated with poor prognosis and advanced stages in myelodysplastic syndrome.Leuk Lymphoma. 2008 Jul;49(7):1297-305. doi: 10.1080/10428190802129918.
|
| 352 |
NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes.Cancer Genet Cytogenet. 2009 Apr 15;190(2):108-12. doi: 10.1016/j.cancergencyto.2008.12.008.
|
| 353 |
The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1.Leukemia. 2019 Aug;33(8):1868-1880. doi: 10.1038/s41375-018-0361-0. Epub 2019 Jan 30.
|
| 354 |
Mutation analysis of the origin recognition complex subunit 5 (ORC5L) gene in adult patients with myeloid leukemias exhibiting deletions of chromosome band 7q22.Hum Genet. 2001 Apr;108(4):304-9. doi: 10.1007/s004390100498.
|
| 355 |
Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a PhaseIIITrial.Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):213-219.e4. doi: 10.1016/j.clml.2018.12.012. Epub 2018 Dec 21.
|
| 356 |
Glycogen synthase kinase-3 and alternative splicing.Wiley Interdiscip Rev RNA. 2018 Nov;9(6):e1501. doi: 10.1002/wrna.1501. Epub 2018 Aug 17.
|
| 357 |
DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome.Br J Haematol. 2003 Oct;123(2):288-96. doi: 10.1046/j.1365-2141.2003.04601.x.
|
| 358 |
Differential profile of PIP4K2A expression in hematological malignancies.Blood Cells Mol Dis. 2015 Oct;55(3):228-35. doi: 10.1016/j.bcmd.2015.06.014. Epub 2015 Jun 30.
|
| 359 |
Overexpression of human CAP10-like protein 46 KD in T-acute lymphoblastic leukemia and acute myelogenous leukemia.Genet Test Mol Biomarkers. 2010 Feb;14(1):127-33. doi: 10.1089/gtmb.2009.0145.
|
| 360 |
Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies.Cancers (Basel). 2019 Oct 3;11(10):1493. doi: 10.3390/cancers11101493.
|
| 361 |
Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes.Oncotarget. 2017 Dec 1;8(70):115002-115017. doi: 10.18632/oncotarget.22839. eCollection 2017 Dec 29.
|
| 362 |
Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.Haematologica. 2020 Jun;105(6):1539-1551. doi: 10.3324/haematol.2019.218453. Epub 2019 Sep 5.
|
| 363 |
Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.Leukemia. 2019 Jun;33(6):1487-1500. doi: 10.1038/s41375-018-0310-y. Epub 2018 Dec 21.
|
| 364 |
Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia.Leukemia. 2001 Jun;15(6):954-62. doi: 10.1038/sj.leu.2402108.
|
| 365 |
Pediatric MDS: GATA screen the germline.Blood. 2016 Mar 17;127(11):1377-8. doi: 10.1182/blood-2016-01-690016.
|
| 366 |
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):401-10. doi: 10.1016/j.clml.2014.03.001. Epub 2014 May 6.
|
| 367 |
DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population.J Hematol Oncol. 2013 Jan 22;6:9. doi: 10.1186/1756-8722-6-9.
|
| 368 |
A rare case of acquired immunodeficiency associated with myelodysplastic syndrome.Mol Genet Genomic Med. 2019 Nov;7(11):e923. doi: 10.1002/mgg3.923. Epub 2019 Sep 10.
|
| 369 |
Mutation in RAP1 is a rare event in myelodysplastic syndromes.Leukemia. 2005 Sep;19(9):1678-80. doi: 10.1038/sj.leu.2403882.
|
| 370 |
Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.Am J Hematol. 2016 May;91(5):492-8. doi: 10.1002/ajh.24332. Epub 2016 Apr 4.
|
| 371 |
"Bone marrow aspirate automated counts on hematology analyzers: formulating a scoring system based on hematology parameters, to discriminate reactive versus myelodysplastic syndrome-related bone marrows".Int J Lab Hematol. 2019 Aug;41(4):542-549. doi: 10.1111/ijlh.13049. Epub 2019 May 18.
|
| 372 |
Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes.Nat Commun. 2015 Nov 26;6:8806. doi: 10.1038/ncomms9806.
|
| 373 |
Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome.Eur J Haematol. 2017 Oct;99(4):323-331. doi: 10.1111/ejh.12920. Epub 2017 Jul 24.
|
| 374 |
RPL27A is a target of miR-595 and may contribute to the myelodysplastic phenotype through ribosomal dysgenesis.Oncotarget. 2016 Jul 26;7(30):47875-47890. doi: 10.18632/oncotarget.10293.
|
| 375 |
p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 2008 Nov 15;68(22):9358-66. doi: 10.1158/0008-5472.CAN-08-1860.
|
| 376 |
Leukemic survival factor SALL4 contributes to defective DNA damage repair.Oncogene. 2016 Nov 24;35(47):6087-6095. doi: 10.1038/onc.2016.146. Epub 2016 May 2.
|
| 377 |
Somatic mosaic monosomy 7 and UPD7q in a child with MIRAGE syndrome caused by a novel SAMD9 mutation.Pediatr Blood Cancer. 2019 Apr;66(4):e27589. doi: 10.1002/pbc.27589. Epub 2018 Dec 19.
|
| 378 |
Outcomes of Hematopoietic Cell Transplantation in Patients with Germline SAMD9/SAMD9L Mutations.Biol Blood Marrow Transplant. 2019 Nov;25(11):2186-2196. doi: 10.1016/j.bbmt.2019.07.007. Epub 2019 Jul 12.
|
| 379 |
Cytogenetic abnormalities and genomic copy number variations in EPO (7q22) and SEC-61(7p11) genes in primary myelodysplastic syndromes.Blood Cells Mol Dis. 2016 Jul;59:52-7. doi: 10.1016/j.bcmd.2016.04.005. Epub 2016 Apr 13.
|
| 380 |
A novel MLL-SEPT2 fusion variant in therapy-related myelodysplastic syndrome.Cancer Genet Cytogenet. 2008 Aug;185(1):62-4. doi: 10.1016/j.cancergencyto.2008.05.002.
|
| 381 |
An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome.Leuk Res. 2007 Aug;31(8):1145-8. doi: 10.1016/j.leukres.2006.12.006. Epub 2007 Jan 23.
|
| 382 |
SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.Pathol Res Pract. 2018 May;214(5):706-712. doi: 10.1016/j.prp.2018.03.010. Epub 2018 Mar 7.
|
| 383 |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
|
| 384 |
Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome.Ann Hematol. 2013 Jan;92(2):199-209. doi: 10.1007/s00277-012-1595-y. Epub 2012 Oct 24.
|
| 385 |
Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice.Cancer Cell. 2003 Jul;4(1):55-65. doi: 10.1016/s1535-6108(03)00163-6.
|
| 386 |
SGCZ mutations are unlikely to be associated with myoclonus dystonia.Neuroscience. 2014 Jul 11;272:88-91. doi: 10.1016/j.neuroscience.2014.04.034. Epub 2014 Apr 30.
|
| 387 |
t(15;21) translocations leading to the concurrent downregulation of RUNX1 and its transcription factor partner genes SIN3A and TCF12 in myeloid disorders.Mol Cancer. 2015 Dec 16;14:211. doi: 10.1186/s12943-015-0484-0.
|
| 388 |
SKI controls MDS-associated chronic TGF- signaling, aberrant splicing, and stem cell fitness.Blood. 2018 Nov 22;132(21):e24-e34. doi: 10.1182/blood-2018-06-860890. Epub 2018 Sep 24.
|
| 389 |
Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features.Cancers (Basel). 2019 Nov 22;11(12):1844. doi: 10.3390/cancers11121844.
|
| 390 |
Differential expression of a novel C-terminally truncated splice form of SMAD5 in hematopoietic stem cells and leukemia.Blood. 2000 Jun 15;95(12):3945-50.
|
| 391 |
SOX7 methylation is an independent prognostic factor in myelodysplastic syndromes.Pathol Res Pract. 2019 Feb;215(2):322-328. doi: 10.1016/j.prp.2018.12.003. Epub 2018 Dec 6.
|
| 392 |
Phenotype of mesenchymal stem cells from patients with myelodyplastic syndrome maybe partly modulated by decitabine.Oncol Lett. 2019 Nov;18(5):4457-4466. doi: 10.3892/ol.2019.10788. Epub 2019 Sep 3.
|
| 393 |
In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies.J Med Chem. 2017 Feb 23;60(4):1523-1533. doi: 10.1021/acs.jmedchem.6b01803. Epub 2017 Feb 2.
|
| 394 |
Discovering transcription and splicing networks in myelodysplastic syndromes.PLoS One. 2013 Nov 14;8(11):e79118. doi: 10.1371/journal.pone.0079118. eCollection 2013.
|
| 395 |
ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.Pathobiology. 2019;86(1):30-38. doi: 10.1159/000489042. Epub 2018 Jun 1.
|
| 396 |
Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies.J Med Genet. 2006 Apr;43(4):e14. doi: 10.1136/jmg.2005.035253.
|
| 397 |
MDR-1 and GST polymorphisms are involved in myelodysplasia progression.Leuk Res. 2013 Aug;37(8):970-3. doi: 10.1016/j.leukres.2013.04.024. Epub 2013 May 17.
|
| 398 |
Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias.Leuk Res. 2009 Dec;33(12):1636-42. doi: 10.1016/j.leukres.2009.03.019. Epub 2009 May 2.
|
| 399 |
Investigation of copy-number variations of C8orf4 in hematological malignancies.Med Oncol. 2011 Dec;28 Suppl 1:S647-52. doi: 10.1007/s12032-010-9698-6. Epub 2010 Sep 29.
|
| 400 |
Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells.Blood. 2001 Nov 1;98(9):2714-9. doi: 10.1182/blood.v98.9.2714.
|
| 401 |
Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.Oncotarget. 2016 Nov 8;7(45):72685-72698. doi: 10.18632/oncotarget.12234.
|
| 402 |
Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome.Histopathology. 2012 Aug;61(2):200-11. doi: 10.1111/j.1365-2559.2012.04209.x. Epub 2012 Jun 13.
|
| 403 |
Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome.Leukemia. 2017 Jul;31(7):1659. doi: 10.1038/leu.2017.95. Epub 2017 Apr 7.
|
| 404 |
Reversion of mtDNA depletion in a patient with TK2 deficiency.Neurology. 2003 Apr 8;60(7):1203-5. doi: 10.1212/01.wnl.0000055928.58122.47.
|
| 405 |
Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis.Blood. 2001 Nov 15;98(10):3058-65. doi: 10.1182/blood.v98.10.3058.
|
| 406 |
From cryptic chromosomal lesions to pathologically relevant genes: integration of SNP-array with gene expression profiling in myelodysplastic syndrome with normal karyotype.Genes Chromosomes Cancer. 2012 May;51(5):419-28. doi: 10.1002/gcc.21927. Epub 2012 Jan 17.
|
| 407 |
Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment.Cureus. 2019 Sep 26;11(9):e5775. doi: 10.7759/cureus.5775.
|
| 408 |
ASXL1 gene alterations in patients with isolated 20q deletion.Neoplasma. 2019 Jul 23;66(4):627-630. doi: 10.4149/neo_2018_181010N754.
|
| 409 |
Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.Expert Opin Investig Drugs. 2019 Oct;28(10):835-849. doi: 10.1080/13543784.2019.1667331. Epub 2019 Sep 19.
|
| 410 |
GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome.Cancer Med. 2017 Jan;6(1):267-274. doi: 10.1002/cam4.984. Epub 2016 Nov 28.
|
| 411 |
Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome.Leuk Res. 2013 Nov;37(11):1538-44. doi: 10.1016/j.leukres.2013.07.022. Epub 2013 Oct 3.
|
| 412 |
Nuclear phospholipase C in biological control and cancer.Crit Rev Eukaryot Gene Expr. 2011;21(3):291-301. doi: 10.1615/critreveukargeneexpr.v21.i3.50.
|
| 413 |
PRDM16 isoforms differentially regulate normal and leukemic hematopoiesis and inflammatory gene signature.J Clin Invest. 2018 Aug 1;128(8):3250-3264. doi: 10.1172/JCI99862. Epub 2018 Jul 23.
|
| 414 |
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.Mol Cancer Res. 2013 Aug;11(8):815-27. doi: 10.1158/1541-7786.MCR-12-0695. Epub 2013 May 3.
|
| 415 |
PURA, the gene encoding Pur-alpha, member of an ancient nucleic acid-binding protein family with mammalian neurological functions.Gene. 2018 Feb 15;643:133-143. doi: 10.1016/j.gene.2017.12.004. Epub 2017 Dec 6.
|
| 416 |
Methylation level of Rap1GAP and the clinical significance in MDS.Oncol Lett. 2018 Dec;16(6):7287-7294. doi: 10.3892/ol.2018.9503. Epub 2018 Sep 26.
|
| 417 |
T-cell receptor Vbeta CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia.Leukemia. 2008 Jun;22(6):1170-4. doi: 10.1038/leu.2008.23. Epub 2008 Mar 6.
|
|
|
|
|
|
|
